March
2010: Protein’eXpert is looking for a head of GMP Production
Company
Funded in 2000 PX’Therapeutics is an expanding Contract Research & Manufacturing
Organisation located in Grenoble and Lyon (France) and with a sales office
in Cambridge (MA, USA). The company is devoted to recombinant protein
engineering & production for biomedical research applications. Our
50-staff company offers custom-designed services focusing on the discovery,
optimisation and production of valuable target or therapeutic proteins.
Recognised as a leading European player in the field of recombinant proteins
manufacturing, PX’Therapeutics possesses extensive expertise in protein expression,
purification and folding in several expression systems (E. coli, yeast, insect
and mammalian cells).
Since 2004, PX’Therapeutics has extended its offering to the biomanufacturing
of therapeutic protein products for early clinical trials (Phase I and II) via
its business unit PX’Pharma. PX’Pharma provides dedicated contract services for
process development & scale-up optimisation, pre-clinical and clinical
cGMP production. In 2007, PX’Therapeutics extended once again its offering via
its business unit, dedicated to monoclonal antibodies development and production.
The combination of PX’Therapeutics, PX’Pharma and PX’Monoclonals know-how and
manufacturing capacities allows ensuring a seamless transfer from therapeutic
protein development up to clinical production stages.
Over the five past years, the company has demonstrated its capability to tackle
highly complex and recalcitrant protein projects and take them to production
stages. PX’Therapeutics has indeed been working on more than 200 protein related
projects, gathering expertise on various target and therapeutic proteins and
building up effective technologies as well as superior management skills.
PX’Therapeutics complies with ISO 9000:2000 international quality standards.
The PX’Pharma facility and equipment have been inspected by AFSSAPS (France)
and comply with the French and European (EMEA) GMP guidelines. PX’Therapeutics is
one of the first biopharmaceutical manufacturers operating in France to be authorized
to release cGMP-grade therapeutic protein candidates.
The position
The post holder will report to the CSO, and will liaise closely with
the Pharma Quality Director.
He/She will be responsible for the process development, scale up optimization,
preclinical and clinical cGMP production of therapeutic recombinant proteins,
including antibodies, in mammalian cell, bacterial and yeast systems. This
will include responsibilities for ensuring each Project is performed in accordance
with cGMP regulatory requirements.
More especially, he/she will be responsible for new technologies selection, validation
and implementation, staff training, scientific and technical troubleshooting,
as well as involved in facilities management, production equipment qualification
and validation.
In addition, he/she will manage a multi-disciplined team of scientists.
Together with the Project Directors team, he/she will be also involved in the
evaluation, planning, management and follow up of therapeutics projects, ensuring
objectives and milestones are met on time and on budget.
Candidate’s
Qualifications and Experience
• An MSc
or PhD degree in biotechnology, biology, biochemistry or cellular biology.
• Between 5 to 15 years experience in the biotechnology industry with strong background
in production of therapeutic recombinant proteins, in GMP environment.
• Good knowledge of cGMP regulatory requirements.
• Previous experience in mammalian cell cultures (CHO,HEK, vero, avian, primary
cells, etc), process development, production (USP), purification (DSP) including
technology transfer and scale up, applied to the preparation of Therapeutic proteins,
including antibodies but also, viruses and or viral vectors.
• Strong organizational and communication skills.